Ultra-early stroke treatment with neuroprotection and clot removal
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a new approach for treating acute ischemic stroke within 4.5 hours of symptoms starting. It combines a special mobile stroke unit that delivers early brain-protecting medicine with standard clot-busting or clot-removal procedures, to see if this can improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have had an ischemic stroke (a clot blocking blood flow in the brain) confirmed by a CT scan
- Treatment can start within 4.5 hours of when your symptoms began
- Your stroke symptoms are moderate to moderately severe (NIHSS score between 6 and 24)
- You are eligible for clot-busting medicine (intravenous thrombolysis) according to standard guidelines
- You or your family agree to join the study and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
This trial tests whether giving a clot-busting drug remotely (via video link with a specialist) can help people having an acute stroke. It aims to see if this approach can improve recovery and outcomes for stroke patients in Oman.
This trial tests an “intra-arterial” approach (a treatment delivered through an artery to the brain) for people with ischemic stroke who were not given clot-busting therapy or a clot-removal procedure. It aims to improve neurological recovery when there wasn’t reperfusion therapy, including in cases where symptoms worsen soon after stroke.
This trial tests if giving a second dose of a clot-busting drug (tenecteplase) helps people who had a stroke and didn't improve much after the first dose. You must receive the second dose within 4.5 hours of your stroke symptoms starting.
This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.
This study tracks people who get a clot-busting medicine for a stroke more than 4.5 hours after symptoms start. It aims to see if this type of treatment is safe and helpful for patients who arrive later, such as after sleeping.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.